Intl Drug Resistance Workshop 15 Sitges 2006

15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain

Resistance implications of monotherapy with lopinavir/r (Kaletra)

Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir

Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients

Epidemiological studies and transmission of resistance: evidence for optimism – or issues with interpretation?

K103N containing variants persist longer in women with subtype D and with higher viral loads

No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine

Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women

High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens

Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates

Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings

Limitations in online tools to identify HIV-1 subtypes

Resistance implications from PrEP and microbicide studies in macaques

Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients

Testing for resistance after starting treatment

5th International Workshop on HIV Drug Resistance, 4-8 June 2001, Scottsdale, Arizona

Anti-HIV immune responses and partial viral suppression

HIV resistance, phenotypic drug susceptibility and viral fitness

SWATCH – alternating antiretroviral regimens

Structured treatments interruptions

Importance of additional active drugs for NNRTI-naive patients using NNRTI-based salvage regimens

NNRTI and PI drug plasma levels are as critical as drug sensitivity in achieving treatment success in antiretroviral experienced patients

Increased prevalence of transmission of drug resistant HIV and reduced response in newly infected subjects in nine US cities

Role of codon-69 variants in reduced susceptibility to nucleoside analogues

Selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive people

Nucleoside resistance pathways may differ between HIV-1 and HIV-2

Role of Y318F mutation in NNRTI resistance